Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LNPEP | Q9UIQ6 | 3/20 | 0.66 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.66 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.54 |
| ▸ | YARS1 | P54577 | 2/20 | 0.52 |
| ▸ | NPY1R | P25929 | 1/20 | 0.52 |
| ▸ | NPY2R | P49146 | 1/20 | 0.52 |
| ▸ | NPY4R | P50391 | 1/20 | 0.52 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.49 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.48 |
| ▸ | NPPA | P01160 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | ECE1 | P42892 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29370934 | 1.00 | LNPEP (0.66) | LNPEPERAP2SLC7A5YARS1NPY1R | |
| SCHEMBL29386049 | 1.00 | LNPEP (0.66) | LNPEPERAP2SLC7A5YARS1NPY1R | |
| SCHEMBL29371447 | 1.00 | LNPEP (0.66) | LNPEPERAP2SLC7A5YARS1NPY1R | |
| SCHEMBL338636 | 1.00 | LNPEP (0.66) | LNPEPERAP2SLC7A5YARS1NPY1R | |
| SCHEMBL29405990 | 0.99 | LNPEP (0.65) | LNPEPERAP2SLC7A5YARS1NPY1R | |
| SCHEMBL30090915 | 0.97 | LNPEP (0.64) | LNPEPERAP2SLC7A5YARS1NPY1R | |
| SCHEMBL30523264 | 0.96 | LNPEP (0.63) | LNPEPERAP2SLC7A5NPY1RNPY2R | |
| SCHEMBL29406227 | 0.96 | LNPEP (0.61) | LNPEPERAP2SLC7A5YARS1NPY1R | |
| SCHEMBL30931517 | 0.95 | LNPEP (0.62) | LNPEPERAP2NPY1RNPY2RNPY4R | |
| SCHEMBL30118045 | 0.95 | LNPEP (0.62) | LNPEPERAP2NPY1RNPY2RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040108-B2 | Amino acid- and peptide-steroid conjugates and use thereof | BRANDEIS UNIVERSITY (US) | 2021-06-22 | — | — | US | claimed |
| US-7052872-B1 | Bi-specific antibodies for pre-targeting diagnosis and therapy | IMMUNOMEDICS, INC. (US) | 2006-05-30 | — | — | US | claimed |
| US-20230124955-A1 | AMINO ACID-, PEPTIDE- AND POLYPEPTIDE-LIPIDS, ISOMERS, COMPOSITIONS, AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-04-20 | — | — | US | disclosed |
| EP-4074694-A1 | AMINO ACID-, PEPTIDE- AN POLYPEPTIDE-LIPIDS, ISOMERS, COMPOSITIONS, AN USES THEREOF | Massachusetts Institute Of Technology (US) | 2022-10-19 | — | — | EP | disclosed |
| US-20200330501-A1 | AMINO ACID-, PEPTIDE- AND POLYPEPTIDE-LIPIDS, ISOMERS, COMPOSITIONS, AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-10-22 | — | — | US | disclosed |
| US-20200197389-A1 | METHODS FOR DETECTING DYSBIOSIS AND TREATING SUBJECTS WITH DYSBIOSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-06-25 | — | — | US | disclosed |
| US-10682374-B2 | Amino acid-, peptide- and polypeptide-lipids, isomers, compositions, and uses thereof | MASSACHUSETTS INTSTITUTE OF TECHNOLOGY (US) | 2020-06-16 | — | — | US | disclosed |
| EP-3634405-A1 | METHODS FOR DETECTING DYSBIOSIS AND TREATING SUBJECTS WITH DYSBIOSIS | The Regents of The University of California (US) | 2020-04-15 | — | — | EP | disclosed |
| US-20190076462-A1 | AMINO ACID-, PEPTIDE- AND POLYPEPTIDE-LIPIDS, ISOMERS, COMPOSITIONS, AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2019-03-14 | — | — | US | disclosed |
| WO-2018209307-A1 | METHODS FOR DETECTING DYSBIOSIS AND TREATING SUBJECTS WITH DYSBIOSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-11-15 | — | — | WO | disclosed |
| US-20180036333-A9 | AMINO ACID-, PEPTIDE- AND POLYPEPTIDE-LIPIDS, ISOMERS, COMPOSITIONS, AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-02-08 | — | — | US | disclosed |
| EP-0522004-B1 | USE OF COPPER(II) CONTAINING COMPOUNDS TO ACCELERATE WOUND HEALING | PROCYTE CORP (US) | 1999-12-15 | — | — | EP | disclosed |
| WO-1999010016-A1 | COMBINATORIAL LIBRARY | RESOLUTION PHARMACEUTICALS INC. (CA) | 1999-03-04 | — | — | WO | disclosed |
| EP-0419387-B1 | Hydrophilic derivatives, diagnostic and therapeutic applications, kits and immunological reagents | IMMUNOTECH PARTNERS (FR) | 1996-11-20 | — | — | EP | disclosed |
| US-H1312-H | Method for the preparation of gyk-dtpa | CYTOGEN CORPORATION (US) | 1994-05-03 | — | — | US | disclosed |
| US-5274076-A | N-alpha-acetyl,N-epsilon(histamine-succinyl-glycl)-L-lysyl-L -tyrosyl-N-epsilon(histamine-succinyl-glycyl)-L-lysylamide | IMMUNOTECH PARTNERS (FR) | 1993-12-28 | — | — | US | disclosed |
| EP-0522004-A1 | USE OF COPPER(II) CONTAINING COMPOUNDS TO ACCELERATE WOUND HEALING | PROCYTE CORPORATION (US) | 1993-01-13 | — | — | EP | disclosed |
| US-5164367-A | Complexes with peptides | PROCYTE CORPORATION (US) | 1992-11-17 | — | — | US | disclosed |
| WO-1991014437-A2 | USE OF COPPER(II) CONTAINING COMPOUNDS TO ACCELERATE WOUND HEALING | PROCYTE CORPORATION (US) | 1991-10-03 | — | — | WO | disclosed |
| EP-0419387-A1 | Hydrophilic derivatives, diagnostic and therapeutic applications, kits and immunological reagents | IMMUNOTECH PARTNERS: Société en Commandite par Actions dite (FR) | 1991-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200330501-A1 | AMINO ACID-, PEPTIDE- AND POLYPEPTIDE-LIPIDS, ISOMERS, COMPOSITIONS, AND USES THEREOF | APLNR, NPPA, ARGLU1 | LNPEP 11/4885ERAP2 535/4885SLC7A5 20/4885 |
| US-11040108-B2 | Amino acid- and peptide-steroid conjugates and use thereof | NGLY1, CD81, MTX1 | LNPEP 41/4885ERAP2 1144/4885SLC7A5 145/4885 |
| US-20230124955-A1 | AMINO ACID-, PEPTIDE- AND POLYPEPTIDE-LIPIDS, ISOMERS, COMPOSITIONS, AND USES THEREOF | APLNR, NPPA, ARGLU1 | LNPEP 11/4885ERAP2 535/4885SLC7A5 20/4885 |
| US-20190076462-A1 | AMINO ACID-, PEPTIDE- AND POLYPEPTIDE-LIPIDS, ISOMERS, COMPOSITIONS, AND USES THEREOF | APLNR, NPPA, ARGLU1 | LNPEP 11/4885ERAP2 535/4885SLC7A5 20/4885 |
| US-20180036333-A9 | AMINO ACID-, PEPTIDE- AND POLYPEPTIDE-LIPIDS, ISOMERS, COMPOSITIONS, AND USES THEREOF | APLNR, NPPA, ARGLU1 | LNPEP 11/4885ERAP2 535/4885SLC7A5 20/4885 |
| US-10682374-B2 | Amino acid-, peptide- and polypeptide-lipids, isomers, compositions, and uses thereof | APLNR, NPPA, ARGLU1 | LNPEP 11/4885ERAP2 535/4885SLC7A5 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.